Cost-Effectiveness of Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone as Adjuvant Therapy for Resected Stage IIIB-IV Melanoma: An Updated Early Economic Evaluation
Year: 2026
Type: preprint
Source: SSRN Electronic Journal
DOI: 10.2139/ssrn.7398098
Author: Yichao Jin
Institution: The University of Texas at Dallas
Language: English
Subfield: Economics and Econometrics
Domain: Social Sciences
Open Access status: green
OpenAlex ID: W7207572900
